Vor Biopharma Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Vor Biopharma Inc. has filed its annual 10-K report for the fiscal year ending December 31, 2023.</b>

AI Summary

Vor Biopharma Inc. (VOR) filed a Annual Report (10-K) with the SEC on March 20, 2024. Vor Biopharma Inc. filed its 2023 Form 10-K on March 20, 2024. The filing covers the fiscal year ending December 31, 2023. The company's principal business is in Biological Products (No Diagnostic Substances). Vor Biopharma Inc. is incorporated in Delaware. The company's business address is 100 Cambridgepark Drive, Suite 101, Cambridge, MA 02140.

Why It Matters

For investors and stakeholders tracking Vor Biopharma Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Vor Biopharma's financial performance, business operations, and risk factors for the fiscal year 2023. Investors and stakeholders can use this report to assess the company's financial health, strategic direction, and potential risks, which is crucial for investment decisions in the biotechnology sector.

Risk Assessment

Risk Level: medium — Vor Biopharma Inc. shows moderate risk based on this filing. The company operates in the highly competitive and regulated biotechnology sector, facing risks related to clinical trial success, regulatory approvals, and market adoption of its products.

Analyst Insight

Review the detailed financial statements and risk factors in the 10-K to understand Vor Biopharma's current financial position and future prospects.

Key Numbers

• 2023-12-31 — Fiscal Year End (Conformed period of report)
• 2024-03-20 — Filing Date (Filed as of date)
• 001-39979 — SEC File Number (SEC file number)

Key Players & Entities

• Vor Biopharma Inc. (company) — Filer name
• 2023 (date) — Fiscal year end
• 2024-03-20 (date) — Filing date
• 100 Cambridgepark Drive, Suite 101, Cambridge, MA 02140 (address) — Business address
• DE (state) — State of incorporation
• 2836 (sic_code) — Standard Industrial Classification

FAQ

Risk Factors

• Competition [high — market]: The company faces intense competition from other biotechnology companies, including large pharmaceutical companies and smaller, more agile firms, which could adversely affect its ability to achieve market penetration and profitability.
• Regulatory Approval [high — regulatory]: The development and commercialization of the company's product candidates are subject to extensive regulatory review and approval processes by agencies such as the FDA, which can be lengthy, costly, and uncertain.
• Funding Requirements [high — financial]: The company will require substantial additional funding to finance its ongoing research and development activities, clinical trials, and potential commercialization efforts, and may not be able to secure such funding on favorable terms or at all.

Key Dates

• 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the 10-K.
• 2024-03-20: Filing Date — Date the 10-K was officially submitted to the SEC.

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share VOR Nasdaq Glob

Filing Documents

• vor-20231231.htm (10-K) — 2623KB
• vor-ex23_1.htm (EX-23.1) — 8KB
• vor-ex31_1.htm (EX-31.1) — 13KB
• vor-ex31_2.htm (EX-31.2) — 15KB
• vor-ex32_1.htm (EX-32.1) — 17KB
• 0000950170-24-034146.txt (&nbsp;) — 9146KB
• vor-20231231.xsd (EX-101.SCH) — 1164KB
• vor-20231231_htm.xml (XML) — 1494KB

Business

Business 5 Item 1A.

Risk Factors

Risk Factors 31 Item 1B. Unresolved Staff Comments 92 Item 1C. Cybersecurity 92 Item 2.

Properties

Properties 93 Item 3.

Legal Proceedings

Legal Proceedings 93 Item 4. Mine Safety Disclosures 93 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 94 Item 6. [Reserved] 94 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 95 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 105 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 105 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 105 Item 9A.

Controls and Procedures

Controls and Procedures 105 Item 9B. Other Information 106 Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 106 Part III Item 10. Directors, Executive Officers and Corporate Governance 107 Item 11.

Executive Compensation

Executive Compensation 107 Item 12

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 107 Item 13 Certain Relationships and Related Transactions, and Director Independence 107 Item 14 Principal Accountant Fees and Services 107 PART IV Item 15. Exhibits and Financial Statement Schedules 108 Item 16 Form 10-K Summary 111 i Note Regarding Company References Throughout this Annual Report on Form 10-K ("Annual Report"), the "Company," "Vor," "Vor Bio," "Vor Biopharma Inc.," "we," "us," and "our," except where the context requires otherwise, refer to Vor Biopharma Inc. and its consolidated subsidiary, and "our board of directors" refers to the board of directors of Vor Biopharma Inc. Special Note Regarding Forward-Looking Statements and Industry Data This Annual Report contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Annual Report, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, and objectives of management, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "might," "intend," "target," "ongoing," "project," "estimate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions intended to identify statements about the future. These statements speak only as of the date of this Annual Report and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by the forward-looking statements. We have based these forward-lo

Bu siness

Item 1. Bu siness. Overview Vor Bio is a clinical-stage company harnessing the power of cell and genome engineering to develop potentially transformative therapies in acute myeloid leukemia ("AML"), a devastating disease with few treatment options. AML is the most common type of acute leukemia in adults and one of the deadliest and most aggressive blood cancers, affecting 20,000 newly diagnosed patients each year in the United States. The traditional tumor targeting approach to treating blood cancers such as AML focuses on cancer cells expressing a target antigen. However, very few targets are tumor-specific, as healthy cells usually express these same target antigens alongside cancer cells. While technologies may improve the specificity of target antigen binding or enhance potency, these approaches are subject to the same fundamental biological limitation of killing healthy cells expressing these targets, known as on-target toxicity. A number of targeted therapies have failed in clinical development, and those that have succeeded possess limited utility and narrow applicability, in part due to their on-target toxicity. Hematopoietic cell transplant ("HCT") is the standard of care for AML, replacing cancerous marrow with cells from a matched healthy donor. Unfortunately, approximately 40% of patients with AML who receive a HCT suffer a relapse of their leukemia and have two-year survival rates of less than 20%. Transplanted hematopoietic stem cells ("HSCs") are fragile following transplant, preventing the use of potentially curative treatment options. Vor Bio's proprietary platform aims to change the entire paradigm of AML treatments by developing highly potent chimeric antigen receptor ("CAR")-T cell therapies to kill cancer, uniquely deriving these treatments from healthy transplant donors. Vor Bio's vision is to couple these CAR-T therapies with shielded HSC transplants, where we genetically engineer healthy donor cells by removing therapeutic targets, th

View Full Filing

View this 10-K filing on SEC EDGAR